ERBB2 and breast cancer: Finally, we further predicted the prognostic value of CEMIP in BC patients by taking the stage, age, molecular subtype, ER/PR/HER2 status, TNM status, and TP53 mutation status into consideration in addition to the expression level of CEMIP using the Cox Proportional Hazards model based on TCGA cohorts.